Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The coding exons and flanking regions of HGF and MET were directly sequenced in 145 lymphedema probands, 59 unrelated women with secondary lymphedema following treatment for breast cancer, 21 individual patients with lymphedema and intestinal lymphangiectasia, and at least 159 unrelated ethnic matched control individuals.
|
18564920 |
2008 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SNPs in TMPRSS3 (rs3814903 and rs11203200), TMPRSS7 (rs1844925), and HGF (rs5745752) associated significantly with breast cancer risk (Ptrend = 0.008-0.042).
|
25029565 |
2014 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The HGF growth factor receptor MET is potentially functionally altered due to an uncommon germline single nucleotide polymorphism (SNP), MET-T1010I, in many cancer lineages including breast cancer where the MET-T1010I SNP is present in 2% of patients with metastatic breast cancer.
|
25605252 |
2015 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that 51% of African Americans and 15% of individuals of mixed European descent with breast cancer harbor a truncated DATE variant (25As or fewer) in their breast tumors and that the truncated allele is associated with cancer incidence and aberrant HGF expression.
|
19188684 |
2009 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetically (siMET) or pharmacologically (INCB28060) targeting MET inhibited both HGF- and pre-OB CM- mediated BC cell migration.
|
26934743 |
2016 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The biological function of the interaction between LINE-1 ORF-1p and the HGF/ETS-1 signaling pathway in regulation of human breast cancer proliferation remains largely unknown.
|
24012497 |
2013 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we investigate the regulation of Brk kinase activity and cell migration in response to treatment of keratinocytes (HaCaT cells) and breast cancer cell lines (MDA-MB-231 and T47D cells) with hepatocyte growth factor (HGF) and macrophage stimulating protein (MSP), peptide ligands for Met and Ron receptors, respectively.
|
20687930 |
2010 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Met and its ligand HGF are associated with clinical outcome in breast cancer.
|
27175600 |
2016 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results of our present study suggest that both IL-6 and HGF derived from CAFs could contribute to the intratumoral androgen metabolism in ER-negative BC patients.
|
28831645 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Understanding how these secondary receptors facilitate HGF/c-Met cellular responses will aid in the development of better therapeutic treatment options for breast cancer patients with elevated HGF signaling.
|
17495520 |
2007 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deregulation of hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) signalling has been associated with poor clinical outcome in breast cancer and other cancers.
|
24910416 |
2014 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated whether HGFK1 is a key regulator of breast cancer bone metastasis.
|
22767217 |
2012 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report that hepatocyte growth factor and hypoxia may contribute to breast carcinoma cell invasiveness by inducing the chemokine receptor CXCR4.
|
16112111 |
2005 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of hepatocyte growth factor/scatter factor receptor (c-Met) in axillary drainage after operations for breast cancer using reverse transcriptase-polymerase chain reaction.
|
12793903 |
2003 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor/scatter factor (HGF/SF), via its receptor c-MET, has been implicated to play a pivotal role in breast cancer development and progression.
|
11489839 |
2001 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current study explored the impact of paxillin suppression on prostate and breast cancer cell function and their responsiveness to hepatocyte growth factor (HGF) and bone matrix extract (BME) in order to assess its potential to influence bone colonization and homing.
|
28739717 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these results demonstrate that miR-335 suppresses breast cancer cell migration by negatively regulating the HGF/c-Met pathway.
|
25492484 |
2015 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate possible roles of HGF in invasive growth of breast carcinomas.
|
17699109 |
2007 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the hepatocyte growth factor (HGF)/c-Met signaling axis has gained considerable attention as a valid molecular target for breast cancer therapy.
|
29978911 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we demonstrate that treatment of breast cancer cells sensitive to EGFR TKIs with recombinant HGF confers a resistance to EGFR TKIs.
|
22788954 |
2012 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of LRIG1 destabilizes endogenous Met receptor in breast cancer cells and impairs their ability to respond to HGF.
|
17178829 |
2007 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extracellular superoxide dismutase inhibits hepatocyte growth factor-mediated breast cancer-fibroblast interactions.
|
29296173 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Microenvironment Stimuli HGF and Hypoxia Differently Affected miR-125b and Ets-1 Function with Opposite Effects on the Invasiveness of Bone Metastatic Cells: A Comparison with Breast Carcinoma Cells.
|
29337876 |
2018 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4.
|
10832594 |
2000 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, decreased cell viability of Met receptor expressing breast cancer cells treated with delphinidin argues for a potential role of the agent in the prevention of HGF-mediated activation of various signaling pathways implicated in breast cancer.
|
18499206 |
2008 |